NTRK-1 fusion in endocervical fibroblastic malignant peripheral nerve sheath tumor marking eligibility for larotrectinib therapy: A case report

摘要

Highlights?<1% of cervical cancers are sarcomas.?Data on neurofibrosarcoma management is scarce.?Larotrectinib is approved for NTRK1 gene fusion tumors without acquired resistance.?Targeted therapy of tumor genes may expand treatment for a rare cervical sarcoma.